Researchers at Biohub reported that co‑administration of three common amino acids dramatically improves lipid nanoparticle (LNP) uptake, increasing mRNA delivery and CRISPR editing efficiency in preclinical models. The team showed that physiological metabolic states suppress certain amino acid pathways, and supplementing those metabolites restores cellular receptivity to LNP fusion. The approach, published in Science Translational Medicine, does not require redesigning LNP formulations and could be applied broadly across mRNA and gene‑editing programs to bridge the gap between in vitro potency and in vivo performance. Investigators caution that translation to humans requires further safety and dosing studies, but they present the method as a potentially low‑barrier enhancement for existing delivery platforms.